How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Artificial Pancreas Device System Market
- By Component Type: Continuous Glucose Monitor (CGM), Insulin Pump, Control Algorithm Software, User Interface Devices
- By End User: Hospitals, Diabetes Clinics, Home Care Settings, Research Institutions
- By Technology Type: Hybrid Closed-Loop Systems, Fully Closed-Loop Systems, Predictive Low Glucose Suspend Systems
- By Age Group: Pediatric Patients, Adult Patients, Geriatric Patients
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Continuous Glucose Monitor (CGM) leads By Component Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.160 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.168 →
Full report · locked preview
Everything inside the Artificial Pancreas Device System Market report
A complete, evidence-based study - 11 chapters and 113 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Component Type 4
End User 4
Technology Type 3
Age Group 3
Companies profiled
Medtronic plc
Insulet Corporation
Tandem Diabetes Care Inc.
Dexcom Inc.
Abbott Laboratories
Roche Diabetes Care
Beta Bionics Inc.
Bigfoot Biomedical Inc.
Senseonics Holdings Inc.
Eli Lilly and Company
Sanofi
Ypsomed AG
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Insulet Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Tandem Diabetes Care Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Dexcom Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Roche Diabetes Care
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Beta Bionics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Bigfoot Biomedical Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Senseonics Holdings Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Eli Lilly and Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Sanofi
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Ypsomed AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Ascensia Diabetes Care
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Valeritas Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Glooko
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,296M by 2033 · 5.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Continuous Glucose Monitor (CGM)41.1
- Insulin Pump22.2
- Control Algorithm Software13.4
- User Interface Devices23.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$289.0M → $389.6M · 3.8%
Europe$201.4M → $324.3M · 6.1%
Asia Pacific$183.9M → $271.4M · 5.0%
Latin America$113.8M → $186.9M · 6.4%
Middle East and Africa$87.6M → $144.8M · 6.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.972026
4.982027
4.992028
5.012029
5.022030
5.032031
5.052032
5.062033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic plc11.2
- Insulet Corporation24.1
- Tandem Diabetes Care Inc.11.4
- Dexcom Inc.10.9
- Abbott Laboratories9.7
- Roche Diabetes Care4.8
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Component Type38.3%
End User18.2%
Technology Type24.5%
Age Group19.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America29.6
- Europe24.6
- Asia Pacific20.6
- Latin America14.2
- Middle East and Africa11.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic plc | 96 | 83 | 83 | 95 | 89 | 78 | 87 |
| Insulet Corporation | 88 | 85 | 91 | 89 | 92 | 68 | 86 |
| Tandem Diabetes Care Inc. | 63 | 67 | 82 | 75 | 86 | 77 | 75 |
| Dexcom Inc. | 66 | 77 | 70 | 57 | 79 | 63 | 69 |
| Abbott Laboratories | 69 | 58 | 54 | 72 | 62 | 56 | 62 |
| Roche Diabetes Care | 49 | 70 | 58 | 54 | 52 | 66 | 58 |
| Beta Bionics Inc. | 64 | 60 | 64 | 54 | 46 | 49 | 56 |
| Bigfoot Biomedical Inc. | 41 | 42 | 52 | 51 | 38 | 37 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic plc
- Insulet Corporation
- Tandem Diabetes Care Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic plc | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Insulet Corporation | ✓ | ✓ | ◐ | ✓ | ◐ | ✓ |
| Tandem Diabetes Care Inc. | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Dexcom Inc. | ◐ | ✓ | ◐ | − | ◐ | ◐ |
| Abbott Laboratories | ◐ | − | − | ✓ | ◐ | ◐ |
| Roche Diabetes Care | − | ◐ | ◐ | − | ◐ | − |
| Beta Bionics Inc. | − | ◐ | ◐ | − | ◐ | − |
| Bigfoot Biomedical Inc. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medtronic plc87
2Insulet Corporation86
3Tandem Diabetes Care Inc.75
4Dexcom Inc.69
5Abbott Laboratories62
6Roche Diabetes Care58
7Beta Bionics Inc.56
8Bigfoot Biomedical Inc.44
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Medtronic plcInsulet Corporation
Challenger2
Strong scale, closing on the leaders.
Tandem Diabetes Care Inc.Dexcom Inc.
Contender2
Focused players with pockets of strength.
Abbott LaboratoriesRoche Diabetes Care
Niche2
Specialists in a single segment or region.
Beta Bionics Inc.Bigfoot Biomedical Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Component Type in North America, then scale across Artificial Pancreas Device System Market — a $141M beachhead inside a $2.32B market.
Beachhead (SOM)$141Mobtainable near-term
Serviceable (SAM)$810Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Continuous Glucose Monitor (CGM)
Best fit — highest urgency & budget in Component Type.
Economic buyer78 fit
Insulin Pump
Strong fit — clear ROI and a fast path to value.
End user67 fit
Control Algorithm Software
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Component Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel27%
Digital / self-serve23%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Component Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Artificial Pancreas Device System Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified25%
Evaluation12%
Closed-won7%
$21.8KCAC
$84KLTV
3.9:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Artificial Pancreas Device System Market is a high-growth opportunity — $7.43B by 2033, compounding at 10.8%.
TAM · 2025$3.28Btoday
TAM · 2033$7.43Bforecast
CAGR10.8%2027–2033
Cumulative$46.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.43BTotal addressable market
SAM$2.59BServiceable available market
SOM$483MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.8% CAGR
Demand compounds through 2033, outpacing GDP across Component Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Component Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.43BLarge & growingTAM by 2033 at 10.8% CAGR
$2.59BServiceable nowreachable with today’s model
$483MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.80BBear7.0% CAGR
$7.43BBase10.8% CAGR
$9.51BBull14.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Artificial Pancreas Device System Market — a $6.53B market by 2033. Plan: grow share from 10.9% to 18.8%.
Market size · 2033$6.53Btotal addressable
Market CAGR5.3%2027–2033
Target share18.8%from 10.9% today
Revenue ambition$1.23Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.9% | 18.8% | On track |
| Revenue | $768M | $1.23B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 29.4% | 40.6% | On track |
| Customer retention | 88.3% | 95.6% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Component Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Component Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $150M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Component Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Artificial Pancreas Device System Market conversation — a $11.5B market you can size, segment and defend in minutes.
Market size · 2033$11.5Btotal opportunity
Growth11.4%CAGR to 2033
Addressable buyers1,494+accounts in scope
Typical ROI6.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Component Type
Goal Grow share in Component Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.2×return on cost, year one
< 4 mopayback period
$54K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Medtronic plcInsulet CorporationTandem Diabetes Care Inc.Dexcom Inc.Abbott LaboratoriesRoche Diabetes CareBeta Bionics Inc.Bigfoot Biomedical Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Artificial Pancreas Device System Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Artificial Pancreas Device System Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Antifungal infection Therapeutics Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportAdvanced Drug Delivery Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportUrsodeoxycholic Acid API Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportWound Cleaning Products Market
Wound Cleaning Products Market is valued at USD 2.85 Billion in 2025 and is expected to reach U…
$2.9B market · 2025 base year
View reportRadiodermatitis Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportClinic Dental Autoclave Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportHospital Dental Autoclave Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportClinic Automatic Dental Autoclave Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportAutomatic Dental Autoclave Market
Market size, share, segmentation and regional forecast.
$359M market · 2025 base year
View reportDesktop Slit Lamp Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportPortable Slit Lamp Market
Market size, share, segmentation and regional forecast.
$428M market · 2025 base year
View reportBlood Component Separator Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.